BMJ  2003;327:344 (9 August), doi:10.1136/bmj.327.7410.344

Letter

Industry funding of patients' support groups

Declaration of competing interests is rare in Italian breast cancer associations

EDITOR—Herxheimer reported and commented on relationships between pharmaceutical companies and consumers' and patients' associations.¹ This is a "hot" topic: the debate on transparency of fund raising for voluntary health associations is far from being resolved, and consumers' umbrella associations have an increasingly important role in discussing health at a European level.

In Italy, at least among the 100 breast cancer associations belonging to the Italian forum of Europa Donna,^{2 3} transparency of fund raising is rarely discussed and few data are available. Using a standardised self administered questionnaire on the characteristics of breast cancer associations, sponsored in part by Komen Italia Onlus, we collected some information on the sponsorship relations of 67 breast cancer associations. Most of the funds come from individual donations, and one third of breast cancer associations received funds from pharmaceutical companies (box).

In the same survey we also asked whether breast cancer associations had prepared a document on the transparency of their relations with a sponsor (declaration of competing interests). Only five breast cancer associations declared that they had done so, and among associations sponsored by pharmaceutical companies only two had prepared this document.

Fundraising by breast cancer associations Individuals Annual subscription: 97% Donation: 89% Through public efforts: 44% Institutions Central government: 14% Local government: 74% Public institutions: 6% Companies Pharmaceutical: 30% Commercial: 42%

These data confirm the concern expressed by Herxheimer and by Hirst⁴ on the independence of consumers' and patients' associations and support the need for more public funding for organisations participating in the debate on public health.

Outcome Research Unit, Istituto di Ricerche, Farmacologiche Mario Negri, Via Eritrea 62, I-20157 Milan, Italy mosconi{at}marionegri.it on behalf of the Italian Forum of Europa Donna

---

Competing interests: None declared.

References

1. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. BMJ 2003;326: 1208-10. (31 May.)[Free Full Text]
2. Mosconi P. Italian Forum Europa Donna. Consumer health information: the role of breast cancer associations. Breast Cancer Res Treatment 2002;76: 89-94.[CrossRef][ISI][Medline]
3. Mosconi P, Kodraliu G, on behalf of Italian Forum of Europa Donna. Italian Forum of Europa Donna: a survey of the breast cancer associations. Health Expectations 1999;2: 44-50.[CrossRef][Medline]
4. Hirst J. Charities and patient groups should declare interests. BMJ 2003;326: 1211. (31 May).[Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Should patient groups accept money from drug companies? No

Barbara Mintzes
BMJ 2007 334: 935. [Extract] [Full Text] [PDF]

Charities and patient groups should declare interests

Jenny Hirst
BMJ 2003 326: 1211. [Extract] [Full Text]

Relationships between the pharmaceutical industry and patients' organisations

Andrew Herxheimer
BMJ 2003 326: 1208-1210. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Mintzes, B. (2007). Should patient groups accept money from drug companies? No. BMJ 334: 935-935 [Full text]